Resmed IncRMD
Price$221.15Intrinsic value$316.6443% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $316.64median of 6 methods · middle span $217-$348based on filings through 30 Jun 2026
Market Price $221.15Price as of 1 Oct 2026
Margin of Safety +43.2%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 13.9% (near-term consensus, capped) · years 2–5: 7.9%/yr (balance of the path).9.1% per year
Years 6–10: glide to demonstrated growth own history 20.7%, capped at 20%
Per-year rates
Yr 68.1%Yr 78.4%Yr 88.6%Yr 98.9%Yr 109.1%
7.9% → 9.1%
Years 11–20: glide to long-run rate
Per-year rates
Yr 118.5%Yr 127.9%Yr 137.3%Yr 146.7%Yr 156.0%Yr 165.4%Yr 174.8%Yr 184.2%Yr 193.6%Yr 203.0%
9.1% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)20.7%
Discount rate (cost of equity) 8.7%
Volatility vs market (adjusted beta)0.84

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetResmed IncRMDHealth Care
Valuation
P/E21.2×
P/S5.8×
P/B5.1×
EV / Revenue5.6×
EV / EBITDA—
Profitability
Gross margin61.1%
Operating margin33.4%
Net margin26.9%
FCF margin29.2%
Returns
ROE23.1%
ROA17.0%
ROIC27.6%
Growth
Revenue growth (YoY)9.9%
5-yr fwd EPS growth9.1%
Financial strength
Debt / Equity0.06×
Current ratio3.10×
Altman Z-Score10.9
Interest coverage—
Dividend yield0.5%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.